Updates are available Correction dated 2021-06-29

Article History

Received: 26 March 2020

Accepted: 31 July 2020

First Online: 9 August 2020

Change Date: 29 June 2021

Change Type: Correction

Change Details: A Correction to this paper has been published:

Change Details: https://doi.org/10.1007/s41999-021-00527-y

Compliance with ethical standards

:

: SR has nothing to declare. MW was employed by AstraZeneca R&D, Mölndal, as director of discovery medicine (= translational medicine) from 2003 to 2006, while on sabbatical leave from his professorship at the University of Heidelberg. Since returning to this position in January 2007, he has received lecturing and consulting fees from Sanofi-Aventis, Bayer, Berlin-Chemie, Boehringer-Ingelheim, Aspen, Novartis, Takeda, Roche, Pfizer, Bristol-Myers, Daichii-Sankyo, Lilly, Otsuka, Novo-Nordisk, Shire, and LEO Pharma.

: The analysis was approved by the ethics committee at the Medical Faculty Mannheim, Heidelberg University (2018-887R-MA).

: Not applicable in this retrospective, fully anonymized analysis.